|Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study|
AT Taher, KM Musallam, M Karimi, A El-Beshlawy, K Belhoul, S Daar, ...
Blood, The Journal of the American Society of Hematology 115 (10), 1886-1892, 2010
|Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study|
A Taher, A El‐Beshlawy, MS Elalfy, K Al Zir, S Daar, D Habr, ...
European journal of haematology 82 (6), 458-465, 2009
|β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint|
V De Sanctis, C Kattamis, D Canatan, AT Soliman, H Elsedfy, M Karimi, ...
Mediterranean journal of hematology and infectious diseases 9 (1), 2017
|Cytokine profile of sickle cell disease in Oman|
A Pathare, S Al Kindi, AA Alnaqdy, S Daar, H Knox‐Macaulay, ...
American journal of hematology 77 (4), 323-328, 2004
|Splenectomy and thrombosis: the case of thalassemia intermedia|
AT Taher, KM Musallam, M Karimi, A El‐Beshlawy, K Belhoul, S Daar, ...
Journal of Thrombosis and Haemostasis 8 (10), 2152-2158, 2010
|Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript|
CM Lucas, RJ Harris, A Giannoudis, A Davies, K Knight, SJ Watmough, ...
haematologica 94 (10), 1362, 2009
|Age‐related complications in treatment‐naive patients with thalassaemia intermedia|
AT Taher, KM Musallam, A El‐Beshlawy, M Karimi, S Daar, K Belhoul, ...
British journal of haematology 150 (4), 486-489, 2010
|Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload|
S Daar, AV Pathare
Annals of hematology 85 (5), 315-319, 2006
|Multicenter validation of spin‐density projection‐assisted R2‐MRI for the noninvasive measurement of liver iron concentration|
TG St Pierre, A El‐Beshlawy, M Elalfy, A Al Jefri, K Al Zir, S Daar, D Habr, ...
Magnetic resonance in medicine 71 (6), 2215-2223, 2014
|Cytokines in sickle cell disease|
A Pathare, SA Kindi, S Daar, D Dennison
Hematology 8 (5), 329-337, 2003
|Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia|
S Daar, A Pathare, H Nick, U Kriemler‐Krahn, A Hmissi, D Habr, A Taher
European journal of haematology 82 (6), 454-457, 2009
|Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates|
S Alkindi, S Al Zadjali, A Al Madhani, S Daar, H Al Haddabi, Q Al Abri, ...
Hemoglobin 34 (2), 135-144, 2010
|Frequency and clinical significance of erythrocyte genetic abnormalities in Omanis.|
JM White, BS Christie, D Nam, S Daar, DR Higgs
Journal of medical genetics 30 (5), 396-400, 1993
|Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major|
A Pathare, A Taher, S Daar
Annals of hematology 89 (4), 405-409, 2010
|JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse|
T Lange, A Edelmann, U Siebolts, R Krahl, C Nehring, N Jäkel, M Cross, ...
haematologica 98 (5), 722, 2013
|Risk factors for pulmonary hypertension in patients with β thalassemia intermedia|
M Karimi, KM Musallam, MD Cappellini, S Daar, A El-Beshlawy, K Belhoul, ...
European Journal of Internal Medicine 22 (6), 607-610, 2011
|Molecular characterization of G6PD deficiency in Oman|
S Daar, TJ Vulliamy, J Kaeda, PJ Mason, L Luzzatto
Human heredity 46 (3), 172-176, 1996
|A community-based study of common hereditary blood disorders in Oman|
AA Al Riyami, AJ Suleiman, M Afifi, ZM Al Lamki, S Daar
EMHJ-Eastern Mediterranean Health Journal, 7 (6), 1004-1011, 2001, 2001
|Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study|
KM Musallam, MD Cappellini, S Daar, M Karimi, A El-Beshlawy, ...
Haematologica 99 (11), e218, 2014
|Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: results from the ESCALATOR trial|
A Taher, A Al Jefri, MS Elalfy, K Al Zir, S Daar, D Rofail, JF Baladi, D Habr, ...
Acta Haematologica 123 (4), 220-225, 2010